Skip to main content

Table 3 P-values of statistical analyses comparing duodenal mRNA levels of selected genes

From: Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

  

Statistical test

P-values

KIAA1199

COX-2

CDH1

PPARD

GSTA1

CASP3

CCND1

CTNNB1

GSTP1

FAP pre-intervention vs. controls

 

Mann–Whitney U

0.253

0.021

0.060

0.438

0.008*

0.001*

0.373

0.269

0.104

FAP: pre- vs. post-intervention

Group A: celecoxib & UDCA

Wilcoxon Signed Rank

0.730

0.826

0.048

0.778

0.272

0.074

0.730

0.272

0.433

Group B: celecoxib & placebo

Wilcoxon Signed Rank

0.046

0.345

0.064

0.279

0.173

0.600

0.075

0.101

0.013

Group A vs. B: median of differences

Mann–Whitney U

0.048

0.720

0.006*

0.583

0.048

0.128

0.259

0.043

0.019

  1. *Statistically significant with correction for multiple testing applied (p < 0.01).
  2. Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, glutathione S-transferase P1.